Pomerantz LLP is investigating Beam Therapeutics and some of its executives for potential securities fraud following a press release on September 8, 2026. The release shared updated clinical trial data for BEAM-302, a treatment for alpha-1 antitrypsin deficiency, noting safety issues including transient liver enzyme elevations. This news caused Beam's stock to fall nearly 10% in one day. The investigation could lead to a class action lawsuit if wrongdoing is found.
The story concerns Beam Therapeutics Inc. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: Among 91 health-sector US stocks priced on Pluang, 59 rose and 31 fell today. Notably, BioNano Genomics Inc (BNGO) gained 9.27% to USD 1.65 with a typical hold time of 49 days, while Novavax Inc (NVAX) rose 8.77% to USD 10.17, attracting 100% buy order activity and a longer hold time of 59 days. Meanwhile, 10X Genomics Inc (TXG) increased 8.02% to USD 78.51 with balanced buy-sell orders and the longest hold time of 94 days among these movers.
Sysco Corporation and Teamsters Locals 630 and 848 have agreed on wages, benefits, and pension terms, but the strike continues due to union demands allowing strikes at any time, risking service disruptions in Los Angeles. Sysco offered an $8 hourly w...
SkyAI, Inc. announced a cash tender offer to buy up to 95% of its common stock and warrants at $3.00 per share, representing a 65% premium over its recent closing price. The offer, expected to start around October 15, 2026, aims to provide liquidity ...
Schall, Brown & Schwartz LLP announced a class action lawsuit against The Chemours Company for allegedly making false and misleading statements about the demand for its Opteon products and providing unreliable fiscal guidance for 2026. The lawsuit cl...
The DJS Law Group has announced a class action lawsuit against The Chemours Company for alleged violations of securities laws. The lawsuit claims Chemours made false and misleading statements about its Opteon product sales and overstated demand, affe...
Kristin Smith of the Solana Policy Institute warns that digital asset regulations finalized by the SEC and CFTC before summer 2028 could be difficult to reverse due to the Congressional Review Act's limited window for overturning rules. With Congress...
